Skip Navigation


NDT Advance Access originally published online on February 22, 2005
Nephrology Dialysis Transplantation 2005 20(5):868-869; doi:10.1093/ndt/gfh746
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/5/868    most recent
gfh746v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Frey, F. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frey, F. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press [2005]

Personal Opinion

Methylation of CpG islands: potential relevance for hypertension and kidney diseases

Felix J. Frey

Department of Nephrology and Hypertension, Inselspital, University of Berne, Switzerland

Correspondence and offprint requests to: Felix J. Frey, MD, Department of Nephrology and Hypertension, Inselspital, University of Berne, Freiburgstrasse 10, CH-3010 Berne, Switzerland. Email: felix.frey@insel.ch

The first 10% of the full text of this article appears below.



   DNA methylation
 
Methylation of DNA is an epigenetic process which modulates gene expression [1]. In the mammalian genome, methylation is almost exclusively observed at cytosines 5' to guanosines, i.e. in the CpG dinucleotides. Many of these CpG islands are associated with promoters [2,3]. Methylation of CpGs in the promoter region has the potential to silence gene expression. Mechanisms accounting for diminished or abrogated gene expression following CpG methylation comprise blocking of the binding of sequence-specific trans-activating proteins or binding of proteins that interfere with transcription [3,4. . . [Full Text of this Article]



   Inhibition of DNA methyltransferase activity
 


   Examples of gene silencing by CpG methylation in the field of hypertension and nephrology
 


   Outlook
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?